Revenue (Tables)

12 Months Ended

Apr. 26, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The table below illustrates net sales by segment and division for fiscal years 2024, 2023, and 2022:

	Net Sales by Fiscal Year
(in millions)	2024		2023		2022
Cardiac Rhythm & Heart Failure	$	5,995	$	5,783	$	5,852
Structural Heart & Aortic	3,358		3,363		3,055
Coronary & Peripheral Vascular	2,478		2,375		2,460
Cardiovascular	11,831		11,522		11,368
Cranial & Spinal Technologies	4,756		4,451		4,456
Specialty Therapies	2,905		2,815		2,592
Neuromodulation	1,746		1,693		1,735
Neuroscience	9,406		8,959		8,784
Surgical & Endoscopy	6,508		6,152		6,543
Acute Care & Monitoring	1,908		1,837		1,926
Medical Surgical	8,417		7,989		8,469
Diabetes	2,488		2,262		2,338
Reportable segment net sales	32,142		30,731		30,959
Other operating segment (1)	221		495		727
Total net sales	$	32,364	$	31,227	$	31,686

(1) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.

The table below illustrates net sales by market geography for each segment for fiscal years 2024, 2023, and 2022:

	U.S.(1)						Non-U.S. Developed Markets(2)						Emerging Markets(3)
(in millions)	Fiscal Year 2024		Fiscal Year 2023		Fiscal Year 2022		Fiscal Year 2024		Fiscal Year 2023		Fiscal Year 2022		Fiscal Year 2024		Fiscal Year 2023		Fiscal Year 2022
Cardiovascular	$	5,597	$	5,796	$	5,490	$	3,857	$	3,564	$	3,866	$	2,377	$	2,161	$	2,012
Neuroscience	6,305		6,018		5,753		1,739		1,658		1,801		1,362		1,283		1,229
Medical Surgical	3,717		3,549		3,659		3,049		2,917		3,155		1,650		1,522		1,655
Diabetes	852		849		974		1,284		1,106		1,085		352		307		279
Reportable segment net sales	16,471		16,212		15,876		9,929		9,245		9,907		5,742		5,273		5,176
Other operating segment (4)	91		160		259		50		163		218		81		172		250
Total net sales	$	16,562	$	16,373	$	16,135	$	9,979	$	9,408	$	10,126	$	5,823	$	5,446	$	5,426

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

(4)Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, which primarily includes the Company's ventilator product line and the Renal Care Solutions business.